Novartis Q4 Results

Content Click below to navigate through the document Strong Q4 growth driven by performance from EntrestoⓇ, KesimptaⓇ, KisqaliⓇ and CosentyxⓇ ↓ ↑ Company overview Financial review Conclusions Appendix References Q4 sales Entresto sacubitril/valsartan Kesimpta (ofatumumab) 20 mg injection KISQALI ribociclib Sales USD million 1,635 641 Growth vs. PY USD million 344 272 610 253 Cosentyx 1,303 223 (secukinumab) 273 PLUVICTO™ 94 LEQVIO® 123 81 • SCEMBLIX® 125 (asciminib) 20 mg. 40 mg tablets 73 ILARIS 376 (canakinumab) 150 ra niezione sottocutanes 75 JAKAVI® 444 56 ruxolitinib Xolair 378 55 Omalizumab FOR SUBCUTANEOUS USE PROMACTA® (eltrombopag) 563 23 GROWTH Growth vs. PY CC 26% 73% 76% Strong growth (+40% cc); 21% * 53% expected to continue 190% 143% 29% 14% 16% 4% * Benefitting from lower prior year base. Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 49 of Condensed Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. □ NOVARTIS | Reimagining Medicine. Novartis Q4 Results | January 31, 2024 6

View entire presentation